Shares of Cue Biopharma surged 9.6% in pre-market trading to $40.01 after the clinical-stage drugmaker announced a $50 million private placement — its second major capital raise in just over two months. The deal, priced at $33.21 per share, immediately raises a critical question: Is smart money buying conviction, or is a tiny company running on fumes simply keeping the lights on?
• Heavyweight Backers Paid Below Market, and That's Actually the Point. The placement was led by Cormorant Asset Management, with additional new funds including Columbia Threadneedle Investments.
Cormorant is a healthcare-focused investment firm founded in 2013 whose portfolio spans biopharma, devices, and diagnostics.
In 2024 alone, Cormorant completed roughly 31 investments totaling about $3.88 billion. That pedigree matters. Institutions buying at a $33.21 price when the stock closed at $36.51 signals they demanded a discount — standard in these deals — but also committed real dollars to a company with a market value recently near $127 million. The $50 million infusion is roughly 40% of the pre-deal market cap, a significant vote of confidence.
• Two Raises in Ten Weeks Means Cash Was Running Dangerously Low. As of March 31, Cue had just $16.4 million in cash; it subsequently completed a $30 million placement and received a $7.5 million milestone payment from Boehringer Ingelheim.
Trailing twelve-month net income was -$26.6 million , meaning even post-April fundraising, the runway was thin. This $50 million buys time — probably into 2028 — but the pattern of repeated dilution is the cost of being a pre-revenue drug developer.
• Existing Shareholders Face Real Dilution. The transaction adds 1,418,071 new shares and up to 87,500 warrant shares, dilutive to existing holders.
Before this deal, Cue had approximately 4.0 million shares outstanding , meaning the new issuance expands the share count by roughly 37%. The stock's rally suggests traders believe the pipeline progress justifies that tradeoff.
• The Real Catalyst Is Data, Not Cash. Cue plans to use net proceeds to support clinical development, with Phase 2 data from a study treating a chronic skin condition in China expected by end of Q3 2026.
Its lead asset is a novel antibody with a dual mechanism, currently in Phase 2 for allergic diseases. That readout will determine whether this stock is a turnaround story or another cash-burning cautionary tale.